Details of the Drug

General Information of Drug (ID: DMZD5QR)

Drug Name
Cytarabine
Synonyms
Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Acute myelogenous leukaemia 2A41 Approved [2]
Adult acute monocytic leukemia N.A. Approved [2]
Childhood acute megakaryoblastic leukemia N.A. Approved [2]
Plasma cell myeloma 2A83.1 Approved [2]
Neoplastic meningitis N.A. Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01BC01: Cytarabine
L01BC: Pyrimidine analogues
L01B: ANTIMETABOLITES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 243.22
Logarithm of the Partition Coefficient (xlogp) -2.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The absorption of drug is less than 20% from the gastrointestinal tract []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 41.67 mL/min/kg [4]
Elimination
11% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 minutes [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.10101 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.87% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.67 L/kg [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cell-mediated cytotoxicity Not Available IL3 OT0CQ35N [6]
Cell-mediated cytotoxicity Not Available HGF OTGHUA23 [6]
Chemical Identifiers
Formula
C9H13N3O5
IUPAC Name
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Canonical SMILES
C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
InChI
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKey
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
Cross-matching ID
PubChem CID
6253
ChEBI ID
CHEBI:28680
CAS Number
147-94-4
UNII
04079A1RDZ
DrugBank ID
DB00987
TTD ID
D07XSN
VARIDT ID
DR00416
INTEDE ID
DR0398
ACDINA ID
D00976
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30) TTIU7X1 DPOL_HHV11 Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Equilibrative nucleoside transporter 2 (SLC29A2) DTW78DQ S29A2_HUMAN Substrate [8]
Concentrative nucleoside transporter 1 (SLC28A1) DT0EQPW S28A1_HUMAN Substrate [8]
Equilibrative nucleoside transporter 1 (SLC29A1) DTXD1TQ S29A1_HUMAN Substrate [8]
Organic cation/carnitine transporter 1 (SLC22A4) DT2EG60 S22A4_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Substrate [13]
Ecto-5'-nucleotidase (NT5E) DE3Z9HM 5NTD_HUMAN Substrate [13]
Deoxycytidylate deaminase (DCTD) DEXL3P2 DCTD_HUMAN Substrate [13]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Substrate [14]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 (PLCB2) OTPAHDGO PLCB2_HUMAN Protein Interaction/Cellular Processes [15]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1 (PLCH1) OT6Z1L2E PLCH1_HUMAN Gene/Protein Processing [16]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Drug Response [17]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Gene/Protein Processing [16]
5'-3' exonuclease PLD3 (PLD3) OTL07SP2 PLD3_HUMAN Gene/Protein Processing [16]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Gene/Protein Processing [16]
A disintegrin and metalloproteinase with thrombospondin motifs 9 (ADAMTS9) OTV3Q0DS ATS9_HUMAN Gene/Protein Processing [16]
Actin filament-associated protein 1-like 2 (AFAP1L2) OTJBI0VN AF1L2_HUMAN Gene/Protein Processing [16]
Actin, alpha cardiac muscle 1 (ACTC1) OTJU04B1 ACTC_HUMAN Gene/Protein Processing [16]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Gene/Protein Processing [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 1.0099 9.7697 -3.3766 24.5314
ES1 GDSC1; GDSC2 -4.5214 -0.7972 -4.6471 54.8565
ES8 GDSC1; GDSC2 -3.0262 -0.8211 -3.0619 40.5573
EW-1 GDSC1; GDSC2 -2.9696 0.8604 -3.2949 40.9912
TC-71 GDSC1; GDSC2 -2.5173 2.3489 -3.276 38.2505
MHH-ES-1 GDSC1; GDSC2 -2.303 2.0527 -2.9386 35.9106
ES5 GDSC1 -2.0341 6.274 -4.454 44.1734
A-673 GDSC1; GDSC2 -1.9405 1.3496 -2.3109 31.3443
EW-7 GDSC1; GDSC2 -1.8408 0.8535 -2.0615 29.6284
H-EMC-SS GDSC1; GDSC2 -1.7885 9.9336 -5.9605 40.5143
ES4 GDSC1; GDSC2 -1.6424 1.073 -1.904 27.8652
U2OS GDSC1; GDSC2 -1.5939 2.5423 -2.3625 29.9048
EW-3 GDSC1; GDSC2 -1.2603 2.7542 -2.0966 27.0863
SK-PN-DW GDSC1; GDSC2 -1.1506 3.6192 -2.3563 27.8731
SJSA-1 GDSC1; GDSC2 -1.1186 4.1327 -2.5554 28.6538
EW-16 GDSC1; GDSC2 -1.0117 3.4313 -2.1312 26.1787
EW-22 GDSC1; GDSC2 -1.0056 2.6451 -1.7846 24.3511
CHSA0108 GDSC1 -0.5078 5.6133 -2.6584 31.5887
SaOS-2 GDSC1; GDSC2 -0.271 7.0339 -3.1321 27.7522
ES7 GDSC1; GDSC2 0.1147 2.1114 -0.3964 11.8038
SK-ES-1 GDSC1; GDSC2 0.1402 3.9696 -1.2506 16.8694
CADO-ES1 GDSC1; GDSC2 0.364 2.563 -0.359 10.6505
G-292 clone A141B1 GDSC1; GDSC2 0.3683 5.5347 -1.8131 19.2956
MG-63 GDSC1; GDSC2 0.5638 5.9933 -1.8689 18.9547
CAL-72 GDSC1; GDSC2 0.7443 6.3382 -1.885 18.466
EW-11 GDSC1; GDSC2 0.9571 6.6824 -1.877 17.7665
HOS GDSC1; GDSC2 0.9848 3.4642 -0.2448 7.9242
ES6 GDSC1; GDSC2 1.1794 7.5507 -2.1271 18.4163
CAL-78 GDSC1; GDSC2 1.4783 10.3947 -3.305 22.9047
HuO9 GDSC1; GDSC2 1.4888 4.1377 -0.1824 6.1779
EW-13 GDSC1; GDSC2 1.7729 4.74 -0.2716 6.0576
HuO-3N1 GDSC1; GDSC2 1.8011 9.1758 -2.4409 18.2302
EW-24 GDSC1; GDSC2 1.8147 5.8405 -0.7794 9.0562
CHSA0011 GDSC1 2.3276 13.434 -4.1482 26.7744
NOS-1 [Human HNSCC] GDSC1; GDSC2 2.5409 5.9416 -0.3352 4.8749
NY GDSC1; GDSC2 2.6517 10.5963 -2.5009 16.3699
EW-18 GDSC1; GDSC2 2.8281 5.976 -0.1802 3.5357
CHSA8926 GDSC1; GDSC2 2.9972 14.313 -4.0742 21.9352
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 161 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC1 -4.5566 -1.7967 -4.5864 67.5468
697 GDSC1; GDSC2 -7.2594 -4.4632 -7.2633 79.9338
NU-DUL-1 GDSC1 -5.7225 -3.5973 -5.7244 81.1826
BV-173 GDSC1; GDSC2 -5.4801 -2.5526 -5.5005 64.1874
HEL GDSC1 -5.3011 -1.7109 -5.3688 73.0084
Karpas-231 GDSC1; GDSC2 -4.8543 -3.0457 -4.8556 58.6995
P12-Ichikawa GDSC1; GDSC2 -4.7689 -1.6279 -4.8186 57.4006
MOLT-16 GDSC1; GDSC2 -4.7244 -3.1001 -4.725 57.4239
KE-37 GDSC1; GDSC2 -4.6842 -3.6579 -4.6842 57.0412
CTV-1 GDSC1; GDSC2 -4.446 -2.0434 -4.4609 54.5514
RCH-ACV GDSC1 -4.4173 -1.7916 -4.4427 66.2473
OCI-AML-5 GDSC1 -4.3956 -0.6906 -4.5278 64.21
P30/OHK GDSC1; GDSC2 -4.2493 -2.5766 -4.2508 52.669
VAL GDSC1; GDSC2 -4.1162 1.7563 -4.8069 50.9811
CML-T1 GDSC1; GDSC2 -4.0105 -2.1665 -4.0147 50.279
SUP-B15 GDSC1; GDSC2 -3.9558 -0.8207 -4.0417 49.7481
JURL-MK1 GDSC1 -3.9332 0.1349 -4.1746 59.1811
OCI-Ly19 GDSC1 -3.882 0.5612 -4.2148 58.2892
HAL-01 GDSC1; GDSC2 -3.7338 -0.3034 -3.8775 47.7017
CTB-1 GDSC1 -3.6585 1.899 -4.3551 55.406
MOLT-4 GDSC1; GDSC2 -3.653 -1.9784 -3.6563 46.7027
Reh GDSC1; GDSC2 -3.5727 -1.1106 -3.6099 45.9846
NALM-6 GDSC1; GDSC2 -3.5419 -2.263 -3.5423 45.58
MLMA GDSC1; GDSC2 -3.5241 0.7538 -3.8723 46.0654
Namalwa GDSC1; GDSC2 -3.4626 0.0762 -3.6526 45.2418
SCC-3 GDSC2 -3.4183 -1.0056 -3.4569 44.4632
JJN-3 GDSC1; GDSC2 -3.2714 4.801 -5.0558 45.796
ALL-SIL GDSC1; GDSC2 -3.2241 0.109 -3.4008 42.9598
Hs 445 GDSC2 -3.153 -0.1186 -3.2832 42.1402
KOPN-8 GDSC1; GDSC2 -3.1377 0.906 -3.4903 42.6136
JeKo-1 GDSC1 -3.0362 -0.5067 -3.1033 50.4254
RPMI-8402 GDSC1; GDSC2 -3.0353 -1.6498 -3.0374 40.505
SU-DHL-5 GDSC1; GDSC2 -3.0088 -1.2086 -3.021 40.2846
LAMA-84 GDSC1; GDSC2 -2.9826 2.0264 -3.6644 42.0402
SU-DHL-8 GDSC2 -2.9036 0.026 -3.0392 39.7295
EM-2 GDSC1; GDSC2 -2.8042 0.7682 -3.0907 39.3115
MY-M12 GDSC1 -2.5564 2.0284 -3.2038 45.8832
WSU-NHL GDSC1; GDSC2 -2.3651 2.4019 -3.132 36.9403
TK [Human B-cell lymphoma] GDSC1; GDSC2 -2.3601 0.2637 -2.4954 34.3695
P32/ISH GDSC1; GDSC2 -2.3494 0.8796 -2.6232 34.8867
CCRF-CEM GDSC1; GDSC2 -2.2676 3.4012 -3.4208 37.3561
ALL-PO GDSC1; GDSC2 -2.262 2.9232 -3.222 36.6935
LC4-1 GDSC1; GDSC2 -2.1562 2.6488 -3.0021 35.3708
ATN-1 GDSC1; GDSC2 -2.1023 -0.4738 -2.1245 31.2438
RS4;11 GDSC1; GDSC2 -2.0952 1.3264 -2.4723 32.8786
GR-ST GDSC1; GDSC2 -2.0163 3.7238 -3.2933 35.6791
ML-2 GDSC1; GDSC2 -2.005 -0.6321 -2.0151 30.2061
H9 GDSC1; GDSC2 -1.6042 -0.0241 -1.6417 26.3241
MHH-PREB-1 GDSC1; GDSC2 -1.4314 6.414 -3.9282 34.9734
PF-382 GDSC1; GDSC2 -1.4277 0.384 -1.5103 24.7863
DB GDSC1; GDSC2 -1.3804 2.9483 -2.3031 28.6384
Granta-519 GDSC1; GDSC2 -1.3752 2.2166 -2.0024 27.1254
Jurkat GDSC1; GDSC2 -1.3708 0.8801 -1.5556 24.7536
SUP-T1 GDSC1; GDSC2 -1.3325 4.0011 -2.7117 30.2695
BL-41 GDSC1; GDSC2 -1.2387 0.1424 -1.2734 22.6424
KCL-22 GDSC1; GDSC2 -1.1898 4.8068 -2.9365 30.5764
BALL-1 GDSC1; GDSC2 -1.1374 4.7473 -2.857 30.0307
NB4 GDSC1 -1.1232 1.6208 -1.512 29.0178
WIL2 NS GDSC1; GDSC2 -1.0142 2.5623 -1.7591 24.2511
BE-13 GDSC1; GDSC2 -0.867 5.2349 -2.821 28.7605
TUR GDSC1; GDSC2 -0.8373 5.0849 -2.721 28.2135
Sc-1 GDSC1 -0.7811 4.2193 -2.259 31.182
EoL-1 GDSC1; GDSC2 -0.7719 1.848 -1.217 20.2097
MOLM-13 GDSC1; GDSC2 -0.7501 2.1078 -1.2954 20.5598
CRO-AP2 GDSC1 -0.7247 3.424 -1.837 28.6846
NKM-1 GDSC1; GDSC2 -0.6437 3.6345 -1.8518 23.2118
Karpas-1106P GDSC1; GDSC2 -0.554 4.1249 -1.9914 23.5941
JSC-1 GDSC1; GDSC2 -0.5415 2.6134 -1.2895 19.6647
ST486 GDSC1; GDSC2 -0.5227 6.5933 -3.1487 28.7438
SR GDSC1; GDSC2 -0.4224 1.6629 -0.773 16.1933
MV4-11 GDSC1; GDSC2 -0.3889 3.6397 -1.6017 20.8413
A4/Fukuda GDSC1; GDSC2 -0.3234 3.1827 -1.3244 19.0073
SU-DHL-6 GDSC1; GDSC2 -0.3172 4.4022 -1.8935 22.1655
JVM-3 GDSC1; GDSC2 -0.3018 3.7116 -1.5501 20.2179
SUP-M2 GDSC1; GDSC2 -0.2765 0.9758 -0.3866 13.3888
DND-41 GDSC1; GDSC2 -0.2087 2.7419 -1.0077 16.7065
RPMI-8866 GDSC1 -0.1987 1.834 -0.6026 17.7741
PL-21 GDSC1 -0.1869 4.9671 -2.0426 27.1069
SU-DHL-16 GDSC1 0.0173 3.4672 -1.1248 20.4684
DoHH2 GDSC1 0.0616 1.3919 -0.1527 13.1869
L-1236 GDSC1; GDSC2 0.0669 4.2578 -1.4595 18.3485
A3/Kawakami GDSC1; GDSC2 0.0672 1.4296 -0.1607 10.6086
NCI-H929 GDSC1; GDSC2 0.0674 4.161 -1.412 18.0724
KG-1 GDSC1; GDSC2 0.0808 2.6578 -0.6802 13.6466
Ku812 GDSC1; GDSC2 0.1052 3.7977 -1.2001 16.6936
DEL GDSC1; GDSC2 0.1218 5.2824 -1.9109 20.6658
MEG-01 GDSC1; GDSC2 0.1459 7.8449 -3.1579 26.4
OCI-M1 GDSC1; GDSC2 0.1553 1.7084 -0.1793 10.3523
SKM-1 GDSC1 0.157 5.6389 -2.0546 25.6061
U-698-M GDSC1; GDSC2 0.1679 7.9592 -3.1953 26.4747
Kasumi-1 GDSC1 0.2496 3.149 -0.7498 16.714
OCI-AML-2 GDSC1; GDSC2 0.2499 3.5123 -0.9253 14.5316
CMK GDSC1 0.2659 1.6985 -0.0601 11.4662
SU-DHL-10 GDSC2 0.3646 17.5372 -7.8039 36.853
MHH-CALL-2 GDSC1; GDSC2 0.4889 3.452 -0.6742 12.1739
L-540 GDSC1; GDSC2 0.6001 2.0243 0.1257 6.8196
MOLT-13 GDSC1; GDSC2 0.6194 3.7935 -0.7254 12.0646
MOLP-8 GDSC1; GDSC2 0.6194 7.0024 -2.324 21.1221
NOMO-1 GDSC1; GDSC2 0.6578 2.4527 -0.0281 7.5778
Mono-Mac-6 GDSC1; GDSC2 0.6842 3.5633 -0.5535 10.7858
WSU-DLCL2 GDSC1; GDSC2 0.6872 4.3385 -0.9366 13.1521
Raji GDSC1; GDSC2 0.7115 2.8968 -0.1984 8.4694
MC116 GDSC1 0.7551 5.8818 -1.6479 20.7553
HL-60 GDSC1; GDSC2 0.7814 3.7155 -0.5439 10.421
RL GDSC1 0.7868 5.1178 -1.2392 17.9773
GA-10 GDSC1; GDSC2 0.8002 7.5219 -2.4289 21.0619
ARH-77 GDSC1; GDSC2 0.8363 2.0848 0.3158 4.8323
CESS GDSC1; GDSC2 0.8386 2.4064 0.1581 5.819
KY821 GDSC1; GDSC2 0.8926 3.2804 -0.2309 8.1098
RPMI-6666 GDSC1; GDSC2 0.9356 3.316 -0.2121 7.8622
IM-9 GDSC1; GDSC2 0.9829 2.0514 0.46 3.469
HC-1 GDSC1; GDSC2 1.0091 3.5317 -0.2583 7.9384
GDM-1 GDSC1; GDSC2 1.0419 2.5965 0.2364 4.7143
QIMR-WIL GDSC1 1.0595 2.6257 0.2362 5.8115
JVM-2 GDSC1; GDSC2 1.1218 3.2954 -0.0478 6.2881
KMOE-2 GDSC1; GDSC2 1.161 8.2723 -2.5029 20.3232
MN-60 GDSC1; GDSC2 1.177 5.4216 -1.065 12.4677
YT GDSC1; GDSC2 1.321 2.7079 0.3965 2.9829
L-428 GDSC1; GDSC2 1.371 6.1233 -1.2594 13.0813
AMO1 GDSC1; GDSC2 1.3958 4.9019 -0.6317 9.212
HH [Human lymphoma] GDSC1; GDSC2 1.4141 6.2579 -1.2923 13.155
OPM-2 GDSC1; GDSC2 1.5009 5.2153 -0.7061 9.396
KMS-11 GDSC1 1.5067 3.9853 -0.0943 6.9522
Ramos.2G6.4C10 GDSC1; GDSC2 1.5197 5.2612 -0.7145 9.3991
ME1 GDSC1; GDSC2 1.5197 4.5495 -0.3625 7.2216
BC-1 GDSC1; GDSC2 1.5418 3.1617 0.3305 2.8983
Jiyoye GDSC1; GDSC2 1.5664 3.6238 0.1249 4.0946
L-363 GDSC1; GDSC2 1.5679 5.6683 -0.8794 10.281
MOLM-16 GDSC1 1.6051 4.9711 -0.5066 9.7932
Karpas-45 GDSC1; GDSC2 1.63 4.7127 -0.3611 6.9428
Loucy GDSC1; GDSC2 1.6398 11.5818 -3.7676 24.2157
RPMI-8226 GDSC1; GDSC2 1.6768 3.791 0.1203 3.8821
Karpas-422 GDSC1; GDSC2 1.708 5.9775 -0.9261 10.2051
OCI-AML-3 GDSC1; GDSC2 1.73 5.1564 -0.5057 7.5928
RC-K8 GDSC1; GDSC2 1.7787 3.3843 0.3774 2.1707
EJM GDSC1; GDSC2 1.7931 6.7606 -1.249 11.8994
KMS-12-BM GDSC1; GDSC2 1.8491 5.567 -0.6204 8.0102
P31/FUJ GDSC1; GDSC2 1.9408 3.3113 0.5022 1.2511
Karpas-299 GDSC1; GDSC2 1.9712 5.2584 -0.3842 6.3005
MM1.S GDSC1; GDSC2 2.036 4.8062 -0.1245 4.6089
EB2 GDSC1; GDSC2 2.1292 4.2205 0.2051 2.5447
Daudi GDSC1; GDSC2 2.2037 4.6602 0.0491 3.2895
Farage GDSC1 2.2211 4.2738 0.2339 2.7959
U266B1 GDSC1; GDSC2 2.2494 5.6805 -0.3988 5.8027
HDLM-2 GDSC1; GDSC2 2.3973 6.9494 -0.9061 8.4739
EHEB GDSC1 2.5156 4.98 0.086 3.2253
KM-H2 GDSC1; GDSC2 2.5584 4.6639 0.2459 1.7262
SUP-HD1 GDSC1; GDSC2 2.6333 4.8035 0.2251 1.7353
LP-1 GDSC1 2.6624 4.2551 0.4619 0.8711
HT GDSC1 2.6738 6.4036 -0.467 6.6563
ROS-50 GDSC1 2.7163 6.6254 -0.5435 7.0864
DG-75 GDSC1; GDSC2 2.748 9.8248 -2.054 13.9676
CA46 GDSC1; GDSC2 2.7528 8.61 -1.4618 10.8398
SK-MM-2 GDSC1; GDSC2 2.8175 8.7494 -1.4846 10.8238
VL51 GDSC1; GDSC2 2.8447 5.5779 0.004 2.5525
Karpas-620 GDSC1; GDSC2 2.9283 4.3384 0.5394 0.3115
SU-DHL-4 GDSC1 3.1443 4.4385 0.5841 0.1907
K-562 GDSC1; GDSC2 3.1828 12.173 -2.8884 16.8954
THP-1 GDSC1 3.5037 4.9218 0.546 0.165
SUP-B8 GDSC1 3.5213 5.4798 0.3562 0.6397
OCI-Ly7 GDSC1 4.2898 21.7977 -6.8007 28.961
⏷ Show the Full List of 161 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCE-4 GDSC1 -1.6366 4.4314 -3.2132 39.5731
FLO-1 GDSC1; GDSC2 -0.7222 8.9909 -4.508 33.8356
ESO-26 GDSC1; GDSC2 -0.5914 2.5127 -1.2974 19.9127
KYSE-220 GDSC1; GDSC2 -0.2338 2.9991 -1.1506 17.6473
OACP4 C GDSC1; GDSC2 0.0738 6.9062 -2.7565 24.9612
ESO-51 GDSC1; GDSC2 0.7123 3.0433 -0.2703 8.919
KYSE-50 GDSC1; GDSC2 1.69 5.5077 -0.7079 8.9277
SK-GT-4 GDSC1; GDSC2 1.8781 11.4432 -3.5091 22.6196
KYAE-1 GDSC1; GDSC2 2.8217 4.3491 0.4933 0.4899
OACM5.1 C GDSC1; GDSC2 3.1176 10.4331 -2.0897 13.3203
TE-12 GDSC1 3.5385 6.5179 -0.0404 2.4179
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2 1.9041 5.1217 -0.3647 6.3302
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-212 GDSC1; GDSC2 -4.5114 0.9633 -5.0048 54.0356
SK-N-MC-IXC GDSC1 -4.4055 -2.219 -4.4142 66.738
NB69 GDSC1; GDSC2 -2.7126 2.3693 -3.4936 39.9995
SiMa GDSC1; GDSC2 -1.9714 4.716 -3.6806 36.6586
SJNB-14 GDSC1; GDSC2 -1.6986 2.1149 -2.3102 30.1557
Kelly GDSC1; GDSC2 -1.4224 1.3919 -1.7602 26.0797
SJNB-5 GDSC1 -1.124 1.6377 -1.5188 29.0647
SJNB-10 GDSC1; GDSC2 -0.8958 4.0797 -2.3081 26.5632
GOTO GDSC1; GDSC2 -0.8661 2.3735 -1.5256 22.3422
SK-N-SH GDSC1; GDSC2 -0.8414 8.7512 -4.5 34.2399
MHH-NB-11 GDSC1 -0.5184 2.1124 -1.0529 22.6236
SK-N-AS GDSC1; GDSC2 -0.3775 4.7493 -2.1178 23.5639
CHP-134 GDSC2 0.0636 2.6671 -0.7016 13.8397
SK-N-BE(2)-M17 GDSC1; GDSC2 0.5672 5.2627 -1.5019 16.8992
SJNB-7 GDSC1; GDSC2 0.8563 6.3507 -1.796 17.6356
SK-N-DZ GDSC1; GDSC2 0.8629 9.2813 -3.2554 24.4953
NH-12 GDSC1; GDSC2 0.9039 6.8391 -2 18.5828
TGW GDSC1; GDSC2 0.9083 8.413 -2.7832 22.3685
SJNB-13 GDSC1; GDSC2 1.2505 3.0995 0.151 4.6896
SJNB-17 GDSC1 1.2964 7.1644 -1.8388 19.8767
GI-ME-N GDSC1; GDSC2 1.3407 7.507 -1.9741 17.1559
CHP-126 GDSC1 1.5973 3.47 0.2204 4.292
KP-N-YN GDSC1; GDSC2 1.6888 9.2357 -2.5589 19.0922
SK-N-FI GDSC1; GDSC2 1.7397 11.1611 -3.4781 22.8682
SJNB-6 GDSC1 1.8399 7.6586 -1.6579 16.9552
IMR-5 GDSC1; GDSC2 1.9104 3.6401 0.3394 2.1607
NB1 GDSC1; GDSC2 2.1703 10.7571 -2.9409 19.5428
LA-N-6 GDSC1 2.2619 11.4531 -3.2158 23.5281
SJNB-12 GDSC1; GDSC2 2.7642 6.8515 -0.6187 6.0778
NB(TU)1 GDSC1; GDSC2 2.7762 4.7089 0.3338 1.1003
KP-N-YS GDSC1 3.3976 5.4953 0.3003 0.931
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1; GDSC2 2.2753 8.8292 -1.9093 14.3448
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-148 GDSC2 -2.671 2.2473 -3.4048 39.5104
HCC1806 GDSC1; GDSC2 -1.8705 1.9438 -2.4331 31.5661
CAL-51 GDSC1; GDSC2 -1.7953 1.1805 -2.1018 29.6077
DU4475 GDSC1; GDSC2 -1.6561 3.3399 -2.7556 31.9327
JIMT-1 GDSC1; GDSC2 -0.1555 5.5484 -2.2967 23.6339
Evsa-T GDSC1; GDSC2 -0.0732 5.8689 -2.3779 23.7317
MDA-MB-231 GDSC1; GDSC2 0.3774 6.4789 -2.2742 21.667
MDA-MB-175-VII GDSC1; GDSC2 0.6982 9.099 -3.3037 25.1909
CAL-120 GDSC1; GDSC2 0.9504 7.1112 -2.097 18.9458
MDA-MB-468 GDSC1; GDSC2 1.0005 9.6805 -3.3398 24.4156
HCC38 GDSC1; GDSC2 1.2165 6.5168 -1.5801 15.3642
Hs 578T GDSC1; GDSC2 1.3093 9.8528 -3.1713 22.8417
CAMA-1 GDSC1; GDSC2 1.4043 5.9169 -1.1301 12.2246
MRK-nu-1 GDSC1; GDSC2 1.5249 3.2535 0.275 3.27
AU565 GDSC1; GDSC2 1.6498 8.5123 -2.2293 17.6031
MDA-MB-415 GDSC1; GDSC2 1.6663 7.9967 -1.9597 16.1768
MDA-MB-453 GDSC1; GDSC2 1.6735 5.81 -0.8693 9.9499
HCC1395 GDSC1; GDSC2 1.6768 8.6212 -2.2623 17.694
MFM-223 GDSC1; GDSC2 1.7039 8.1533 -2.0083 16.3293
CAL-85-1 GDSC1; GDSC2 1.8246 4.6262 -0.1804 5.3865
MDA-MB-157 GDSC1; GDSC2 1.8467 5.977 -0.8229 9.2413
MCF-7 GDSC1; GDSC2 1.8523 4.8199 -0.2547 5.7771
EFM-19 GDSC1; GDSC2 1.959 7.0292 -1.2575 11.533
HCC1937 GDSC1; GDSC2 2.0389 9.3545 -2.3462 17.1472
MDA-MB-436 GDSC1; GDSC2 2.1811 9.1733 -2.1489 15.8081
UACC-893 GDSC1 2.2433 8.5118 -1.7768 16.4178
HCC2157 GDSC1; GDSC2 2.3362 4.7491 0.0871 2.8588
MDA-MB-361 GDSC1; GDSC2 2.3765 6.677 -0.7894 7.8378
HCC1419 GDSC1; GDSC2 2.4364 9.3626 -2.053 14.6946
HCC1569 GDSC1 2.4577 8.0872 -1.4145 13.578
HDQ-P1 GDSC1; GDSC2 2.5234 9.0731 -1.8481 13.4293
COLO 824 GDSC1; GDSC2 2.5653 7.4077 -1.0119 8.7239
BT-483 GDSC1; GDSC2 2.6452 4.4463 0.3785 1.0373
BT-474 GDSC1; GDSC2 2.722 4.5149 0.3864 0.9366
EFM-192A GDSC1; GDSC2 3.0109 4.8901 0.3674 0.7809
HCC1428 GDSC1; GDSC2 3.0391 9.4306 -1.6608 11.2924
BT-549 GDSC1; GDSC2 3.1009 13.191 -3.4456 19.381
HCC1143 GDSC1; GDSC2 3.1198 10.5163 -2.1283 13.5068
HCC2218 GDSC1 3.2731 5.0738 0.4067 0.6204
HCC70 GDSC1; GDSC2 3.3305 11.175 -2.3006 13.8889
T-47D GDSC1; GDSC2 3.3629 7.1126 -0.3842 3.8149
BT-20 GDSC1; GDSC2 3.5411 4.8928 0.5687 0.0984
HCC1187 GDSC1; GDSC2 3.5475 11.3284 -2.2264 13.0777
UACC-812 GDSC2 3.5689 5.3808 0.4103 0.3593
OCUB-M GDSC1; GDSC2 3.6057 5.2955 0.454 0.2563
HCC202 GDSC1 3.6454 20.3072 -6.5474 29.7823
HCC1500 GDSC1; GDSC2 3.678 5.2544 0.4942 0.1702
MDA-MB-330 GDSC1 3.7747 11.0155 -1.9271 13.2209
HCC1954 GDSC1; GDSC2 4.0517 5.9273 0.3964 0.2367
ZR-75-30 GDSC1; GDSC2 4.1114 12.1892 -2.2627 12.1318
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC1; GDSC2 -2.619 0.7318 -2.8797 37.4441
LN-18 GDSC1; GDSC2 -2.0352 5.3477 -4.0297 37.8936
MOG-G-UVW GDSC1; GDSC2 -1.9664 1.5463 -2.4014 31.8985
D-566MG GDSC1 -1.807 0.9197 -2.0418 36.3895
D-423MG GDSC1 -1.7019 2.9374 -2.6358 38.187
YKG-1 GDSC1 -1.6618 2.5747 -2.4473 37.2113
H4 GDSC1; GDSC2 -1.5182 1.8471 -2.0185 27.8665
SF126 GDSC1 -1.3395 5.2132 -3.2735 38.0524
LNZTA3WT4 GDSC1 -1.3198 7.8634 -4.5153 40.7524
MOG-G-CCM GDSC1; GDSC2 -1.2675 2.2184 -1.8884 26.0486
ONS-76 GDSC1; GDSC2 -1.1151 5.1018 -3.0005 30.5144
8-MG-BA GDSC1; GDSC2 -0.976 2.7257 -1.7877 24.2411
SK-MG-1 GDSC1; GDSC2 -0.8355 4.9153 -2.639 27.8469
YH-13 GDSC1; GDSC2 -0.7558 5.7699 -2.9697 28.93
Daoy GDSC1; GDSC2 -0.583 0.7959 -0.6764 16.3719
D-336MG GDSC1 -0.4399 3.8121 -1.7326 26.601
Becker GDSC1; GDSC2 -0.3948 5.0455 -2.2769 24.4256
SF539 GDSC1; GDSC2 -0.382 4.3633 -1.9372 22.6441
U-251MG GDSC1; GDSC2 0.003 3.4413 -1.1261 16.6197
D-247MG GDSC1 0.0718 7.7028 -3.1533 30.9535
SF268 GDSC1; GDSC2 0.1144 7.3372 -2.9339 25.587
D-263MG GDSC1; GDSC2 0.2701 5.2609 -1.7656 19.3671
GI-1 GDSC1; GDSC2 0.2836 8.482 -3.3536 26.7057
AM-38 GDSC1; GDSC2 0.3098 3.1272 -0.6821 12.8336
GaMG GDSC1; GDSC2 0.6023 7.1509 -2.4128 21.6098
NMC-G1 GDSC1 0.6881 4.6763 -1.1041 17.4331
A-172 GDSC1; GDSC2 0.9868 5.8737 -1.4479 15.284
42-MG-BA GDSC1; GDSC2 1.188 6.3304 -1.5102 15.0504
SF295 GDSC1 1.2099 3.389 -0.0244 7.3468
U-118MG GDSC1; GDSC2 1.3341 8.1912 -2.3211 18.9423
SW1783 GDSC1; GDSC2 1.3458 6.4363 -1.4356 14.1746
DBTRG-05MG GDSC1; GDSC2 1.4641 7.5109 -1.8773 16.2949
T98G GDSC1; GDSC2 1.4835 4.4387 -0.3349 7.1404
LN-229 GDSC1; GDSC2 1.5005 7.9838 -2.084 17.2779
M059J GDSC1; GDSC2 1.5238 4.3173 -0.2449 6.4807
GB-1 GDSC1; GDSC2 1.5276 3.9698 -0.0715 5.3945
U-87MG ATCC GDSC1; GDSC2 1.6479 9.7818 -2.8633 20.5857
D-502MG GDSC1 1.8036 8.5903 -2.148 19.8947
KNS-81-FD GDSC1 1.8137 10.5854 -3.1326 24.5574
DK-MG GDSC1; GDSC2 1.8222 4.2119 0.0168 4.201
KALS-1 GDSC1; GDSC2 1.8547 3.8858 0.192 3.0992
Onda 11 GDSC1 1.9386 12.1554 -3.8161 26.7831
SW1088 GDSC1; GDSC2 1.9833 4.9794 -0.2419 5.4173
D-392MG GDSC1; GDSC2 2.0324 6.5267 -0.9573 9.5996
CAS-1 GDSC1; GDSC2 2.0658 4.9365 -0.1666 4.7989
SNB-75 GDSC1 2.0888 6.1437 -0.7307 10.0073
KNS-42 GDSC1 2.242 4.5369 0.1281 3.4682
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 2.3027 5.7065 -0.3763 5.5634
KINGS-1 GDSC1; GDSC2 2.3418 7.3557 -1.1409 9.9548
Onda 10 GDSC1 2.5127 5.0254 0.0643 3.3727
Hs 683 GDSC1 2.5229 12.2891 -3.4311 23.6388
LN-405 GDSC1; GDSC2 2.6559 4.6388 0.3052 1.3412
D-542MG GDSC1 2.6843 16.5637 -5.4266 29.4705
PFSK-1 GDSC1; GDSC2 3.2194 11.1313 -2.3564 14.3948
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1; GDSC2 1.1887 9.5428 -3.1152 22.9582
TGBC24TKB GDSC1; GDSC2 1.7361 6.3431 -1.0857 11.0865
TGBC1TKB GDSC1; GDSC2 2.236 6.9729 -1.0296 9.5517
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFE-296 GDSC1; GDSC2 -0.1825 2.9648 -1.0837 17.0569
MFE-319 GDSC1; GDSC2 0.2435 2.5816 -0.4847 11.8566
RL95-2 GDSC1; GDSC2 0.3284 8.6418 -3.394 26.7129
AN3-CA GDSC1; GDSC2 1.5238 4.7269 -0.447 7.7359
ESS-1 GDSC1; GDSC2 1.6459 5.8045 -0.8875 10.1296
KLE GDSC1; GDSC2 2.2852 4.626 0.113 2.7986
EN GDSC1; GDSC2 2.6297 8.8198 -1.649 12.1278
MFE-280 GDSC1; GDSC2 3.5118 5.9484 0.1752 1.0991
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB2241-RCC GDSC1 -4.1125 -0.2233 -4.2993 61.1509
Caki-1 GDSC1 -3.7388 0.5522 -4.0566 57.091
BB65-RCC GDSC1 -3.2341 1.2993 -3.7059 52.1893
LB1047-RCC GDSC1 -2.9971 3.1339 -4.0861 49.9775
KTCTL-140 GDSC1 -2.5119 1.1228 -2.8668 44.908
KTCTL-1M GDSC1 -2.0098 1.9777 -2.5955 40.1711
769-P GDSC1; GDSC2 -1.7155 3.0306 -2.6883 31.9335
KTCTL-13 GDSC1 -1.5957 4.6571 -3.2737 39.4949
BFTC-909 GDSC1; GDSC2 -1.542 4.3212 -3.0679 32.6363
ACHN GDSC1; GDSC2 -1.4512 1.4482 -1.8097 26.4742
KTCTL-195 GDSC1; GDSC2 -1.2132 2.3231 -1.8718 25.7195
KTCTL-26A GDSC1 -0.8533 6.9424 -3.6285 36.5976
SW13 GDSC1; GDSC2 -0.5603 3.3953 -1.6587 21.8279
786-O GDSC1; GDSC2 -0.4614 3.7372 -1.7187 21.7707
LB996-RCC GDSC2 -0.4261 1.9466 -0.8881 16.8712
SW156 GDSC1 -0.2926 3.8802 -1.6209 25.1981
HA7-RCC GDSC1 -0.1988 5.1698 -2.1523 27.7408
CAL-54 GDSC1; GDSC2 -0.1295 4.3644 -1.6964 20.3958
KMRC-1 GDSC1; GDSC2 -0.098 2.9068 -0.9729 16.0782
RXF 393L GDSC1 -0.0362 8.8814 -3.8343 33.6642
UO-31 GDSC1 0.2276 3.4057 -0.8947 17.875
NCC010 GDSC1 0.258 9.4429 -3.8547 32.5829
VMRC-RCW GDSC1 0.8548 3.7478 -0.4967 12.2981
KMRC-20 GDSC1; GDSC2 1.0414 4.2671 -0.5992 9.9896
SN12C GDSC1; GDSC2 1.3249 6.2306 -1.3497 13.7369
NCC021 GDSC1 1.5544 9.1544 -2.6249 23.1429
RCC10RGB GDSC1; GDSC2 1.5956 4.2731 -0.1706 5.8473
VMRC-RCZ GDSC1; GDSC2 1.6112 4.6661 -0.352 6.9316
TK-10 GDSC1; GDSC2 1.6309 5.6829 -0.8387 9.8721
KTCTL-21 GDSC1 1.9143 4.3294 0.0217 4.9603
OS-RC-2 GDSC1; GDSC2 1.9736 8.0538 -1.752 14.2623
A-704 GDSC1; GDSC2 2.266 9.8397 -2.4142 16.8986
A-498 GDSC1; GDSC2 4.6369 17.9475 -4.6675 20.469
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GP5d GDSC1; GDSC2 -2.7624 4.3791 -4.3474 42.1579
HCT 116 GDSC1; GDSC2 -2.2555 3.1361 -3.3002 36.9155
LS513 GDSC1 -1.7089 3.1154 -2.7166 38.5148
SNU-175 GDSC2 -1.6605 6.1577 -4.0312 36.2265
C2BBe1 GDSC1; GDSC2 -1.5862 3.8108 -2.8864 32.1373
SW620 GDSC1; GDSC2 -1.4138 1.6808 -1.8472 26.4982
RKO GDSC1; GDSC2 -1.3564 0.5708 -1.4684 24.2252
SK-CO-1 GDSC1; GDSC2 -1.1861 1.6073 -1.5755 24.0124
COLO 320HSR GDSC1; GDSC2 -0.9382 5.7163 -3.1191 30.2474
HCC2998 GDSC1; GDSC2 -0.8355 4.2408 -2.3228 26.3857
CW-2 GDSC1; GDSC2 -0.8056 6.2896 -3.2675 30.2801
MDST8 GDSC1; GDSC2 -0.7638 2.6729 -1.5447 22.0198
SW48 GDSC1; GDSC2 -0.7116 4.5092 -2.3264 25.9014
LS411N GDSC1; GDSC2 -0.5804 5.4458 -2.6465 26.8697
LoVo GDSC1; GDSC2 -0.2781 6.4196 -2.8369 26.563
HT-29 GDSC1; GDSC2 0.5129 4.3783 -1.1105 14.7689
SW1463 GDSC1; GDSC2 0.5444 4.9984 -1.3905 16.3288
SNU-C5 GDSC1; GDSC2 0.5568 10.799 -4.2735 28.9966
SNU-81 GDSC1 0.6812 4.2857 -0.9155 16.1138
DiFi GDSC1; GDSC2 0.8226 5.2835 -1.2913 14.8678
HCT 15 GDSC1; GDSC2 0.9311 5.5776 -1.3465 14.8621
SNU-407 GDSC1; GDSC2 0.9939 4.4202 -0.7152 10.8509
LS180 GDSC1; GDSC2 1.0792 4.9289 -0.8989 11.7376
CL-11 GDSC1; GDSC2 1.2302 5.1222 -0.8726 11.1474
SW626 GDSC1; GDSC2 1.3627 5.1453 -0.7787 10.2074
KM12 GDSC1; GDSC2 1.4158 5.9206 -1.1229 12.1504
RCM-1 [Human ESC] GDSC1; GDSC2 1.4629 5.6902 -0.9714 11.1138
NCI-H747 GDSC1; GDSC2 1.4961 4.6684 -0.439 7.7562
HT115 GDSC1 1.5581 6.1765 -1.1391 14.5099
HT-55 GDSC1; GDSC2 1.7401 10.0548 -2.9264 20.6102
COLO205 GDSC1; GDSC2 1.8341 5.4008 -0.5499 7.6165
SW1116 GDSC1; GDSC2 1.8351 5.0262 -0.3667 6.4972
NCI-H508 GDSC1 1.9612 6.3565 -0.9256 11.7577
LS123 GDSC1; GDSC2 2.3176 4.1311 0.3483 1.5281
SW948 GDSC1; GDSC2 2.3922 13.6317 -4.1965 23.7781
CCK-81 GDSC1; GDSC2 2.418 4.8543 0.0869 2.7322
SNU-C2B GDSC1; GDSC2 2.4972 6.6615 -0.7013 7.0722
CaR-1 GDSC1; GDSC2 2.5638 5.3406 -0.0472 3.2294
SW837 GDSC1; GDSC2 2.5999 5.5075 -0.1013 3.4664
LS1034 GDSC1; GDSC2 2.6735 4.8154 0.2405 1.6161
SNU-61 GDSC1; GDSC2 2.7564 9.1385 -1.7147 12.1928
SW1417 GDSC1; GDSC2 2.7643 5.5075 -0.0088 2.7282
T84 GDSC1; GDSC2 2.9121 5.1412 0.2225 1.4395
SNU-C1 GDSC1; GDSC2 2.9817 5.3123 0.1859 1.528
COLO 678 GDSC1; GDSC2 3.067 6.108 -0.1066 2.8115
NCI-H716 GDSC1; GDSC2 3.0952 4.9039 0.3977 0.6239
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 1.0121 4.3329 -0.6564 10.4314
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 GDSC1; GDSC2 -3.3758 2.8521 -4.3839 45.7106
Hep 3B2.1-7 GDSC1 -1.561 5.0922 -3.4376 39.7194
SNU-387 GDSC1; GDSC2 -0.5792 7.4766 -3.6331 30.7145
SNU-423 GDSC1; GDSC2 1.0168 12.9402 -4.9561 29.6308
JHH-6 GDSC1; GDSC2 1.0591 5.6078 -1.2548 13.9419
HLE GDSC1; GDSC2 1.442 4.6394 -0.4658 8.0609
Hep-G2/C3A GDSC1; GDSC2 1.5578 7.3707 -1.7333 15.2577
JHH-4 GDSC1; GDSC2 1.7046 3.856 0.1079 3.898
JHH-7 GDSC1; GDSC2 1.8595 4.4204 -0.0578 4.5711
HuH-1 GDSC1; GDSC2 1.9214 12.6729 -4.0875 24.5906
SK-HEP-1 GDSC1; GDSC2 2.2014 7.4659 -1.2946 11.159
JHH-2 GDSC1; GDSC2 2.2089 5.4945 -0.3372 5.5209
SNU-449 GDSC1; GDSC2 2.5455 6.3025 -0.5005 5.814
Huh-7 GDSC1; GDSC2 3.2023 13.4773 -3.512 19.4108
JHH-1 GDSC1; GDSC2 4.5961 14.7347 -3.1512 15.0948
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 179 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1944 GDSC1; GDSC2 -5.43 1.0371 -6.0274 59.9059
A-427 GDSC1 -4.6582 0.3104 -5.0013 64.3654
NCI-H292 GDSC1 -3.3271 -0.2991 -3.4415 53.6594
SBC-3 GDSC1; GDSC2 -3.141 2.0347 -3.8388 43.4002
NCI-H1703 GDSC1; GDSC2 -3.1291 2.5805 -4.0187 43.6565
NCI-H2369 GDSC1; GDSC2 -2.8347 9.1074 -6.5684 45.0764
NCI-H2023 GDSC1; GDSC2 -2.7044 2.7641 -3.6317 40.3163
HOP-62 GDSC1; GDSC2 -2.4271 2.0429 -3.069 37.0603
LC-2/ad GDSC1 -2.3892 3.3354 -3.5219 45.084
A-549 GDSC1; GDSC2 -2.3667 1.3875 -2.7869 35.6661
NCI-H290 GDSC1 -2.2139 2.1985 -2.8947 42.573
NCI-H460 GDSC1 -2.2034 1.4979 -2.6437 41.7864
NCI-H647 GDSC1 -2.1254 7.549 -5.1408 45.3622
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2 -1.7889 5.1336 -3.6847 35.8232
NCI-H510A GDSC1 -1.7076 7.9445 -4.9244 43.1546
HCC44 GDSC1; GDSC2 -1.6816 3.6537 -2.9164 32.7003
NCI-H1155 GDSC1; GDSC2 -1.5889 1.6822 -2.0373 28.2935
LXF 289 GDSC1; GDSC2 -1.5357 3.7385 -2.803 31.5677
EMC-BAC-2 GDSC1; GDSC2 -1.2991 4.9768 -3.1238 31.7714
HCC827 GDSC1; GDSC2 -1.1658 5.0403 -3.0216 30.8107
NCI-H2110 GDSC1 -1.0939 4.7367 -2.8091 35.1947
NCI-H1355 GDSC1; GDSC2 -1.0823 3.0844 -2.0514 26.0775
Lu-99A GDSC1; GDSC2 -1.0676 2.5568 -1.8128 24.7688
NCI-H23 GDSC1; GDSC2 -0.9542 2.6354 -1.7269 23.8205
NCI-H1623 GDSC1; GDSC2 -0.9348 6.855 -3.6631 32.1623
NCI-H211 GDSC1; GDSC2 -0.9316 7.4658 -3.9562 33.0655
NCI-H1734 GDSC1 -0.8972 5.0856 -2.7797 34.0357
COR-L311 GDSC2 -0.8949 3.9239 -2.2357 26.2073
NCI-H2373 GDSC1; GDSC2 -0.8694 4.4806 -2.468 27.2108
NCI-H2122 GDSC1; GDSC2 -0.753 3.7186 -1.9996 24.4315
NCI-H2030 GDSC1 -0.7353 2.4263 -1.4104 26.1714
COR-L105 GDSC1; GDSC2 -0.7159 92.6578 -46.2666 48.0814
COLO 668 GDSC1; GDSC2 -0.6931 3.8003 -1.9775 24.0743
NCI-H1781 GDSC1; GDSC2 -0.5568 6.2453 -3.0111 28.3273
NCI-H1437 GDSC1 -0.5376 6.2862 -3.013 33.1294
NCI-H838 GDSC1 -0.4658 6.67 -3.1333 33.2304
NCI-H1048 GDSC1; GDSC2 -0.4631 4.8811 -2.2629 24.6177
HOP-92 GDSC1; GDSC2 -0.4072 6.7031 -3.095 28.1026
NCI-H2228 GDSC1; GDSC2 -0.3145 10.0231 -4.6489 32.8127
LK-2 GDSC1; GDSC2 -0.1641 6.5257 -2.7843 25.9225
NCI-H1975 GDSC1; GDSC2 0.0345 7.9948 -3.3314 27.4539
IST-SL2 GDSC1; GDSC2 0.0768 3.8916 -1.2724 17.2223
HCC78 GDSC1; GDSC2 0.1882 3.7952 -1.1208 15.9284
SK-MES-1 GDSC1; GDSC2 0.1983 4.8969 -1.6512 18.9786
NCI-H3122 GDSC1; GDSC2 0.2172 4.7388 -1.5561 18.3761
DMS 114 GDSC1; GDSC2 0.3037 7.0363 -2.6164 23.5471
LCLC-97TM1 GDSC1; GDSC2 0.3302 6.4793 -2.3161 22.0318
COR-L23 GDSC1; GDSC2 0.391 4.9405 -1.4982 17.4563
PC-14 GDSC1; GDSC2 0.4555 4.9291 -1.435 16.8777
ABC-1 GDSC1 0.4805 28.2339 -13.0522 43.21
EBC-1 GDSC1; GDSC2 0.5118 5.7324 -1.7844 18.6643
NCI-H2009 GDSC1; GDSC2 0.5125 6.8988 -2.3649 21.6675
NCI-H1876 GDSC1; GDSC2 0.5281 3.233 -0.5306 11.1507
IST-SL1 GDSC1 0.5508 7.5606 -2.6618 26.9733
NCI-H526 GDSC1; GDSC2 0.5766 2.9831 -0.3633 9.9452
RERF-LC-MS GDSC1 0.6212 3.105 -0.3828 12.3428
NCI-H2722 GDSC1; GDSC2 0.6379 16.8058 -7.2066 35.3054
RERF-LC-KJ GDSC1; GDSC2 0.6589 7.466 -2.5214 21.9464
NCI-H2731 GDSC1; GDSC2 0.6981 5.6059 -1.5592 16.8087
LB647-SCLC GDSC1 0.7322 8.6218 -3.0363 27.8867
NCI-H2172 GDSC1 0.7381 7.7284 -2.5849 25.8875
NCI-H2803 GDSC1 0.7688 9.4924 -3.4404 29.3057
RERF-LC-Sq1 GDSC1; GDSC2 0.7736 7.9428 -2.6618 22.2365
NCI-H1299 GDSC1; GDSC2 0.8121 7.4539 -2.3849 20.8121
DMS 273 GDSC1; GDSC2 0.8261 4.3265 -0.8102 11.9429
SW1271 GDSC1; GDSC2 0.8717 6.3125 -1.7639 17.4128
ChaGo-K-1 GDSC1 0.8935 16.6136 -6.8957 37.0337
NCI-H1792 GDSC1; GDSC2 1.0083 4.149 -0.5676 9.8879
NCI-H1755 GDSC1; GDSC2 1.0833 9.1419 -3.0018 22.7923
NCI-H847 GDSC1; GDSC2 1.1005 2.2935 0.435 3.2957
NCI-H2170 GDSC1; GDSC2 1.1072 7.1624 -1.9923 17.9303
SBC-5 GDSC1; GDSC2 1.1368 2.4735 0.3739 3.584
EPLC-272H GDSC1; GDSC2 1.1446 9.8531 -3.3066 23.8615
NCI-H841 GDSC1; GDSC2 1.1447 10.8459 -3.8029 25.7163
NCI-H82 GDSC1; GDSC2 1.2366 9.3616 -2.9853 22.2732
NCI-H209 GDSC1; GDSC2 1.29 5.4653 -0.9958 11.7317
NCI-H1105 GDSC1 1.3006 4.1959 -0.3549 9.6156
NCI-H1581 GDSC1; GDSC2 1.3347 7.408 -1.9295 16.9375
NCI-H2810 GDSC1 1.4397 7.2361 -1.7596 18.9044
NCI-H661 GDSC1; GDSC2 1.4622 5.5703 -0.9124 10.7584
Lu-139 GDSC1 1.4756 3.8312 -0.0414 6.6384
NCI-H2227 GDSC1 1.4761 4.3826 -0.3128 8.7251
SK-LU-1 GDSC1; GDSC2 1.4832 5.5702 -0.8959 10.6029
NCI-H2461 GDSC1; GDSC2 1.4996 9.1201 -2.6516 20.0455
NCI-H720 GDSC1; GDSC2 1.506 3.0617 0.3543 2.8299
NCI-H146 GDSC1 1.5495 6.5928 -1.3527 15.9742
LCLC-103H GDSC1; GDSC2 1.5617 3.7323 0.0689 4.4486
NCI-H2595 GDSC1; GDSC2 1.5769 6.461 -1.2659 12.5611
NCI-H2029 GDSC1 1.5957 3.3851 0.2599 3.9989
NCI-H226 GDSC1; GDSC2 1.6492 3.9993 0.0009 4.6687
NCI-H2087 GDSC1; GDSC2 1.6724 6.85 -1.3852 12.999
BEN GDSC1 1.675 9.1805 -2.5422 22.3429
NCI-H2085 GDSC1; GDSC2 1.7044 5.2632 -0.5768 8.0907
CPC-N GDSC1; GDSC2 1.7384 5.6782 -0.7558 9.0998
Lu-135 GDSC1; GDSC2 1.775 3.6657 0.2444 2.9445
COR-L32 GDSC2 1.7985 4.3837 -0.0815 4.8433
Ms-1 GDSC1; GDSC2 1.8241 4.4377 -0.09 4.8397
NCI-H1341 GDSC1; GDSC2 1.8303 3.5514 0.3319 2.3385
NCI-H1666 GDSC1; GDSC2 1.8607 6.4512 -1.0458 10.5377
SBC-1 GDSC1 1.8723 3.7677 0.2579 3.3454
NCI-H2347 GDSC1; GDSC2 1.8727 8.1552 -1.8788 15.2016
NCI-H2405 GDSC1; GDSC2 1.8779 5.6295 -0.6302 8.0023
NCI-H2795 GDSC1; GDSC2 1.8895 4.3368 0.0019 4.1524
Lu-134-A GDSC1 1.8914 4.8004 -0.2184 6.8007
NCI-H1650 GDSC1; GDSC2 1.904 5.1637 -0.385 6.4539
NCI-H1651 GDSC1; GDSC2 1.9076 5.0108 -0.3087 5.9829
CAL-12T GDSC1 1.948 6.3879 -0.9506 11.9721
NCI-H2066 GDSC1; GDSC2 2.0131 11.9664 -3.6635 22.85
NCI-H322M GDSC1; GDSC2 2.0189 4.3712 0.069 3.5072
NCI-H2869 GDSC1 2.034 11.342 -3.3366 24.7034
NCI-H1693 GDSC1; GDSC2 2.1298 7.91 -1.5646 12.8473
NCI-H187 GDSC1 2.1526 4.6595 0.0183 4.4241
NCI-H810 GDSC1; GDSC2 2.1551 6.8391 -1.0219 9.6927
NCI-H446 GDSC1; GDSC2 2.1564 7.6058 -1.3957 11.8398
LOU-NH91 GDSC1; GDSC2 2.1577 10.8402 -2.9918 19.7941
NCI-H2291 GDSC1 2.1908 9.5859 -2.3455 19.7176
NCI-H650 GDSC1; GDSC2 2.2309 5.5925 -0.3692 5.6656
SHP-77 GDSC1; GDSC2 2.231 7.6817 -1.3788 11.5661
NCI-H1694 GDSC1; GDSC2 2.2493 4.1066 0.3228 1.7432
NCI-H358 GDSC1; GDSC2 2.2778 6.8948 -0.9624 9.0648
NCI-H196 GDSC1; GDSC2 2.2946 4.3689 0.2328 2.1427
NCI-H1963 GDSC1; GDSC2 2.3063 5.6347 -0.3401 5.3449
NCI-H1869 GDSC1; GDSC2 2.3193 6.7151 -0.8468 8.2972
NCI-H441 GDSC1; GDSC2 2.3299 5.6811 -0.3468 5.3377
NCI-H513 GDSC1; GDSC2 2.3463 7.9713 -1.4373 11.6221
NCI-H524 GDSC1; GDSC2 2.3596 4.4288 0.2422 2.0024
KNS-62 GDSC1; GDSC2 2.361 10.2194 -2.5305 17.2131
NCI-H345 GDSC1 2.3626 3.3656 0.6722 0.2813
NCI-H69 GDSC1; GDSC2 2.4214 4.1215 0.4044 1.1475
NCI-H1573 GDSC1; GDSC2 2.4546 7.7113 -1.2343 10.2334
NCI-H2818 GDSC1; GDSC2 2.4556 18.0261 -6.3325 29.4231
COR-L88 GDSC1; GDSC2 2.456 4.331 0.3343 1.4287
NCI-H2591 GDSC1; GDSC2 2.4665 5.4123 -0.1369 3.8841
Calu-3 GDSC1; GDSC2 2.4863 7.5442 -1.1315 9.5784
PaCa-3 GDSC1; GDSC2 2.5326 9.7325 -2.1642 15.024
Lu-165 GDSC1; GDSC2 2.5677 3.8702 0.5684 0.4083
NCI-H2804 GDSC1 2.5841 5.1235 0.0607 3.2657
UMC-11 GDSC1; GDSC2 2.601 9.1652 -1.8375 13.1931
SW1573 GDSC1; GDSC2 2.6164 8.3834 -1.4468 11.0583
VMRC-LCD GDSC1; GDSC2 2.6217 12.8352 -3.6264 21.1961
NCI-H1563 GDSC1; GDSC2 2.6318 16.2808 -5.3267 26.5957
NCI-H1793 GDSC1; GDSC2 2.6654 4.78 0.2512 1.5753
NCI-H727 GDSC1; GDSC2 2.6851 7.3257 -0.8928 7.794
NCI-H1838 GDSC1; GDSC2 2.6903 5.3718 0.0102 2.7348
NCI-H1993 GDSC1; GDSC2 2.7077 4.6793 0.3135 1.2513
EMC-BAC-1 GDSC1 2.7131 7.743 -1.0729 10.6777
NCI-H1648 GDSC1; GDSC2 2.7265 4.8554 0.2501 1.5124
NCI-H2141 GDSC1; GDSC2 2.743 4.7406 0.3053 1.2513
NCI-H1568 GDSC1; GDSC2 2.7612 8.9449 -1.6177 11.6653
NCI-H596 GDSC1; GDSC2 2.7963 4.5268 0.4148 0.7691
Calu-6 GDSC1; GDSC2 2.8251 7.6342 -0.9473 7.8229
NCI-H1304 GDSC1 2.8591 4.6486 0.3949 0.989
LC-1/sq GDSC1; GDSC2 2.8623 11.2727 -2.6791 16.6968
NCI-H2342 GDSC1; GDSC2 2.8785 6.685 -0.4714 5.0451
DMS 79 GDSC1 2.8901 4.7875 0.3544 1.1462
NCI-H1092 GDSC1; GDSC2 2.8903 4.617 0.4206 0.6813
NCI-H522 GDSC2 2.8999 11.1052 -2.57 16.1112
COR-L279 GDSC1; GDSC2 2.903 4.5609 0.4473 0.5848
IA-LM GDSC1; GDSC2 2.9508 9.9537 -1.9738 13.1043
NCI-H2081 GDSC1 2.9816 17.521 -5.6728 29.3392
COR-L321 GDSC1 2.9962 4.7785 0.4038 0.8305
NCI-H3255 GDSC1 3.0679 5.1175 0.3039 1.2056
Lu-65 GDSC1; GDSC2 3.103 5.1165 0.3198 0.883
NCI-H1915 GDSC1; GDSC2 3.1691 11.1995 -2.4247 14.8277
NCI-H2135 GDSC1 3.2542 4.6078 0.5651 0.1958
NCI-H1435 GDSC1; GDSC2 3.2764 5.0428 0.4194 0.4619
NCI-H1436 GDSC1 3.2834 4.7352 0.5317 0.2566
NCI-H1770 GDSC1 3.329 4.6575 0.5745 0.1588
NCI-H1836 GDSC1 3.4128 4.8166 0.5499 0.1808
COR-L95 GDSC1 3.424 16.2321 -4.7024 25.6511
DMS 53 GDSC1; GDSC2 3.4892 13.5556 -3.3436 18.116
NCI-H835 GDSC1; GDSC2 3.4958 5.3898 0.379 0.4654
NCI-H1688 GDSC1; GDSC2 3.5885 5.3486 0.4291 0.3114
NCI-H2444 GDSC1 3.6103 16.4049 -4.6501 25.043
HCC366 GDSC1 3.8111 12.4861 -2.6029 16.6092
HCC15 GDSC1; GDSC2 4.193 13.0407 -2.6125 13.5737
NCI-H64 GDSC1; GDSC2 4.3347 12.6683 -2.3443 12.0899
EKVX GDSC1 4.8411 7.7203 0.0572 0.8492
NCI-H520 GDSC1; GDSC2 6.17 17.5656 -3.4732 13.6095
⏷ Show the Full List of 179 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 2.6063 4.7892 0.2174 1.8053
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
T.T GDSC1; GDSC2 -2.6831 3.9539 -4.0855 41.2367
TE-8 GDSC1; GDSC2 -1.6902 1.2566 -2.0098 28.6359
KYSE-510 GDSC1 -1.6691 1.1182 -1.946 34.9528
EC-GI-10 GDSC1; GDSC2 -0.7915 4.587 -2.4412 26.7684
OE19 GDSC1; GDSC2 -0.2039 7.6306 -3.3652 28.4084
KYSE-180 GDSC1; GDSC2 -0.1566 7.7812 -3.3969 28.3597
KYSE-70 GDSC1; GDSC2 -0.1459 5.3412 -2.1865 23.0511
KYSE-270 GDSC1; GDSC2 -0.0131 3.0625 -0.9621 15.6968
TE-4 GDSC1; GDSC2 0.2162 8.4868 -3.4151 27.1601
TE-9 GDSC1; GDSC2 0.2223 4.2064 -1.2898 16.8151
KYSE-140 GDSC1; GDSC2 0.2893 8.6601 -3.4373 27.0032
TE-5 GDSC1; GDSC2 0.3636 5.0154 -1.56 17.9011
OE21 GDSC1; GDSC2 0.5382 6.3854 -2.0866 20.1876
TE-15 GDSC1 0.8002 2.3241 0.1649 7.3472
KYSE-410 GDSC1; GDSC2 1.253 8.8194 -2.701 20.9737
TE-10 GDSC1 1.2966 4.3176 -0.4185 10.1175
OE33 GDSC1; GDSC2 1.3297 10.6853 -3.5707 24.3469
TE-11 GDSC1 1.46 3.7688 -0.0223 6.5373
KYSE-450 GDSC1; GDSC2 1.5094 4.386 -0.2895 6.7929
COLO 680N GDSC1; GDSC2 2.1268 4.8991 -0.1095 4.3431
KYSE-150 GDSC1; GDSC2 2.453 4.4699 0.274 1.7206
TE-6 GDSC1; GDSC2 2.6238 10.1012 -2.2785 15.3712
KYSE-520 GDSC1; GDSC2 3.2806 7.0085 -0.3839 3.9325
TE-1 GDSC1; GDSC2 3.5455 5.2241 0.4569 0.2691
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVK18 GDSC1 -2.9499 2.2165 -3.6949 49.5668
A2780 GDSC1; GDSC2 -2.5384 2.5746 -3.3823 38.6936
OVCAR-8 GDSC1; GDSC2 -2.2905 3.5873 -3.5219 37.7762
OVCAR-5 GDSC1; GDSC2 -1.8372 3.821 -3.1494 34.3115
ES-2 GDSC1; GDSC2 -1.8343 2.4393 -2.578 32.0359
TOV-21G GDSC1; GDSC2 -1.809 3.6936 -3.0653 33.8715
OV56 GDSC1; GDSC2 -1.6949 2.1813 -2.3309 30.2357
JHOS-2 GDSC1 -1.1791 3.7637 -2.4498 34.2483
OVTOKO GDSC1; GDSC2 -0.981 3.6613 -2.203 26.4066
DOV13 GDSC1; GDSC2 -0.8754 2.6198 -1.6381 23.0029
TOV-112D GDSC1; GDSC2 -0.8391 2.0695 -1.3745 21.3832
OC 314 GDSC1; GDSC2 -0.4028 3.1506 -1.389 19.6869
TYK-nu GDSC1; GDSC2 -0.3506 2.8825 -1.2145 18.4729
OAW42 GDSC1; GDSC2 0.7748 4.7961 -1.0889 13.806
EFO-27 GDSC1 0.7871 7.2246 -2.2915 24.2587
IGROV-1 GDSC1; GDSC2 0.9048 3.212 -0.1863 7.7918
SK-OV-3 GDSC1; GDSC2 1.0224 6.7083 -1.8355 17.3459
Caov-4 GDSC1; GDSC2 1.3158 16.5461 -6.5115 32.4233
OVCAR-3 GDSC1; GDSC2 1.3981 3.854 -0.1104 5.9534
OVISE GDSC1; GDSC2 1.75 4.762 -0.2985 6.275
JHOS-4 GDSC1 1.9516 13.5767 -4.514 28.9817
OAW28 GDSC1; GDSC2 2.036 6.4653 -0.9247 9.3982
RMG-I GDSC1; GDSC2 2.3758 4.9531 0.0182 3.1728
OVCAR-4 GDSC1; GDSC2 2.6736 12.1523 -3.2502 19.5973
FU-OV-1 GDSC1; GDSC2 3.0118 8.4676 -1.2197 8.9685
Kuramochi GDSC1; GDSC2 3.2285 9.0998 -1.3773 9.3938
OV-90 GDSC1; GDSC2 3.2441 12.5462 -3.0265 17.3513
EFO-21 GDSC1; GDSC2 4.271 14.561 -3.2862 16.2677
OVKATE GDSC1; GDSC2 5.4374 25.9863 -8.0157 27.1748
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuP-T4 GDSC1; GDSC2 -1.6312 2.3626 -2.3318 29.9362
PSN1 GDSC1; GDSC2 -1.4018 2.5908 -2.1785 28.1307
KP-4 GDSC1; GDSC2 -0.8445 1.3984 -1.1344 20.0636
SUIT-2 GDSC1; GDSC2 -0.5365 3.1069 -1.5036 20.866
SU.86.86 GDSC1; GDSC2 -0.4116 5.3791 -2.4541 25.3415
HuP-T3 GDSC1; GDSC2 -0.3775 5.7345 -2.5946 25.8624
Capan-1 GDSC1; GDSC2 0.0151 6.138 -2.4298 23.6671
PaTu 8988t GDSC1; GDSC2 0.0603 5.0748 -1.8652 20.6368
CFPAC-1 GDSC1; GDSC2 0.3899 5.4309 -1.7424 18.8359
MZ-PC-1 GDSC1 0.6087 4.4601 -1.0661 17.486
MIA PaCa-2 GDSC1; GDSC2 0.638 3.8282 -0.7261 12.0093
Panc 10.05 GDSC1; GDSC2 0.7575 3.8806 -0.6471 11.1404
Panc 03.27 GDSC1; GDSC2 0.8663 5.0101 -1.1175 13.6982
KP-1N GDSC1; GDSC2 1.0282 8.3328 -2.6429 21.3714
HPAC GDSC1; GDSC2 1.0825 11.343 -4.1029 26.9142
Panc 02.03 GDSC1; GDSC2 1.326 9.0634 -2.7634 21.0445
PL4 GDSC1; GDSC2 1.3297 6.0643 -1.263 13.2165
QGP-1 GDSC1 1.3365 2.9312 0.2984 4.427
DAN-G GDSC1; GDSC2 1.5506 8.6452 -2.3739 18.5897
KP-3 GDSC1; GDSC2 1.562 6.6256 -1.3593 13.143
PaTu 8902 GDSC1; GDSC2 1.6259 5.4879 -0.7461 9.321
HPAF-II GDSC1; GDSC2 1.8135 4.5221 -0.1379 5.1525
SW1990 GDSC1; GDSC2 2.0817 9.8874 -2.5776 18.1386
BxPC-3 GDSC1; GDSC2 2.0873 7.4508 -1.3702 11.863
AsPC-1 GDSC1; GDSC2 2.3072 11.4056 -3.1576 20.114
Capan-2 GDSC1; GDSC2 2.5856 8.7013 -1.6226 12.0856
YAPC GDSC1; GDSC2 2.6142 9.3118 -1.8996 13.486
Panc 04.03 GDSC1; GDSC2 2.7012 6.6956 -0.5857 6.0074
Panc 08.13 GDSC1; GDSC2 2.975 7.8739 -0.9634 7.6199
KP-2 GDSC1; GDSC2 3.1348 7.4157 -0.6516 5.5993
Hs 766T GDSC1; GDSC2 4.1327 11.2155 -1.7929 9.8295
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; GDSC2 -1.8191 3.2804 -2.9006 33.2955
MPP 89 GDSC1; GDSC2 0.6661 4.6689 -1.1196 14.3315
NCI-H28 GDSC1; GDSC2 1.2929 4.4383 -0.4816 8.5519
NCI-H2452 GDSC1; GDSC2 1.5303 4.5417 -0.3506 7.1215
NCI-H2052 GDSC1; GDSC2 1.6317 7.636 -1.8073 15.459
IST-Mes1 GDSC1; GDSC2 2.3542 6.6529 -0.7931 7.9068
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC1; GDSC2 0.3242 5.2089 -1.6911 18.772
PC-3 GDSC1; GDSC2 1.1751 5.6881 -1.1998 13.2801
VCaP GDSC1; GDSC2 1.4726 6.5726 -1.4029 13.6364
22Rv1 GDSC1; GDSC2 2.2581 6.0897 -0.5881 6.9041
DU145 GDSC1; GDSC2 3.3179 5.1296 0.4041 0.4832
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2 1.8359 9.3228 -2.487 18.3569
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-mel GDSC1 -3.2689 1.5793 -3.8289 52.4166
WT2-iPS GDSC1; GDSC2 -3.2567 0.0839 -3.4312 43.264
A-375 GDSC1; GDSC2 -2.631 -0.3877 -2.6877 36.7055
Mel JuSo GDSC1; GDSC2 -2.6261 4.6642 -4.3287 41.4194
Hs 938.T GDSC1 -2.1226 7.7439 -5.2301 45.4264
A2058 GDSC1; GDSC2 -2.1032 0.5819 -2.2823 32.0281
MZ-MEL-2 GDSC1 -1.8052 3.853 -3.1303 40.3807
WM793 GDSC1; GDSC2 -1.7129 5.7774 -3.9053 36.113
LOX-IMVI GDSC1; GDSC2 -1.6554 2.009 -2.2248 29.5392
IGR-37 GDSC1; GDSC2 -1.2592 2.2849 -1.9055 26.1011
M14 GDSC1; GDSC2 -1.1914 2.0839 -1.7553 25.0054
COLO 800 GDSC1 -1.1115 1.6286 -1.5022 28.8878
RPMI-7951 GDSC1; GDSC2 -0.8621 3.3772 -1.9549 24.6474
IST-MEL1 GDSC1; GDSC2 -0.7224 2.3287 -1.3563 20.7878
MeWo GDSC1; GDSC2 -0.6051 1.3604 -0.8619 17.4869
HMV-II GDSC1; GDSC2 -0.524 7.1173 -3.406 29.7153
SK-MEL-28 GDSC1 -0.3982 2.7772 -1.2152 23.1096
WM35 GDSC1; GDSC2 -0.1521 6.2455 -2.6355 25.2188
SK-MEL-2 GDSC1; GDSC2 -0.1488 4.6844 -1.8695 21.4112
WM278 GDSC1; GDSC2 0.0319 4.8387 -1.7758 20.2513
A101D GDSC1; GDSC2 0.0788 4.5336 -1.583 19.0113
451Lu GDSC1 0.1413 7.7352 -3.1075 30.4925
IPC-298 GDSC1 0.2635 3.4206 -0.868 17.522
A-388 GDSC1 0.3501 5.769 -1.9457 24.1704
Mel Ho GDSC1 0.3603 5.264 -1.686 22.6076
IGR-1 GDSC1; GDSC2 0.3801 4.6613 -1.3699 16.7493
CHL-1 GDSC1; GDSC2 0.4039 5.0871 -1.5593 17.7626
A-431 GDSC1 0.5056 6.9206 -2.3818 25.8276
COLO 679 GDSC1; GDSC2 0.8531 4.2769 -0.7624 11.5643
DJM-1 GDSC1 0.9963 5.5025 -1.2544 17.2785
WM1552C GDSC1; GDSC2 1.1831 3.1404 0.0783 5.325
SK-MEL-30 GDSC1 1.2547 4.9585 -0.7712 12.9165
UACC-62 GDSC1; GDSC2 1.2645 6.4391 -1.5024 14.7863
SK-MEL-24 GDSC1; GDSC2 1.2711 7.02 -1.7872 16.3547
LB2518-MEL GDSC1 1.3867 3.6707 -0.0284 6.8089
COLO 792 GDSC1; GDSC2 1.4372 9.7018 -2.9921 21.7292
MMAc-SF GDSC1 1.4736 4.2052 -0.227 8.0746
GAK GDSC1; GDSC2 1.4847 7.3169 -1.7642 15.6274
SK-MEL-1 GDSC1; GDSC2 1.5944 4.5545 -0.3095 6.7091
SH-4 GDSC1; GDSC2 1.7223 4.7667 -0.3206 6.4742
WM115 GDSC1; GDSC2 1.7484 5.9329 -0.8739 9.7892
COLO 829 GDSC1; GDSC2 1.7659 3.5387 0.298 2.6487
CP50-MEL-B GDSC1 1.968 3.9055 0.2528 3.1727
HT-144 GDSC1; GDSC2 1.9836 7.4697 -1.4562 12.6048
MZ-MEL-7 GDSC1 2.0121 11.9874 -3.6747 26.057
COLO 783 GDSC1 2.353 9.2652 -2.0664 17.7417
Hs 940.T GDSC1 2.4918 13.7184 -4.1628 26.364
SK-MEL-31 GDSC1 2.6226 13.0754 -3.7445 24.5496
LB373-MEL-D GDSC1 2.7756 16.6478 -5.3979 29.17
RVH-421 GDSC1 2.9478 12.3091 -3.1248 21.1984
VMRC-MELG GDSC1 3.4571 12.7842 -2.9912 19.2789
G-361 GDSC1; GDSC2 3.9747 18.463 -5.3935 23.9089
SK-MEL-3 GDSC1 4.3983 14.3487 -3.0989 17.4991
CP66-MEL GDSC1 4.5919 13.8312 -2.726 15.4032
SK-MEL-5 GDSC1 5.0355 17.4842 -4.1699 20.2712
UACC-257 GDSC1; GDSC2 5.0903 15.8098 -3.3365 14.9217
EquiPSC Line K2 GDSC1 0.2423 31.7141 -14.9929 44.4009
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -0.5467 3.535 -1.7093 27.0102
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW982 GDSC1; GDSC2 -5.9114 -0.1136 -6.2703 63.9807
MFH-ino GDSC1; GDSC2 -3.6835 1.6023 -4.2876 47.6726
VA-ES-BJ GDSC1; GDSC2 -3.281 1.5991 -3.8483 44.3269
Rh30 GDSC1; GDSC2 -3.1679 5.3815 -5.1985 45.3919
KYM-1 GDSC1; GDSC2 -2.7536 0.8133 -3.047 38.855
Hs 633.T GDSC1; GDSC2 -2.5092 1.8462 -3.0901 37.591
HT-1080 GDSC1; GDSC2 -2.4443 0.4268 -2.6193 35.3828
G-402 GDSC1; GDSC2 -2.2581 3.1976 -3.3277 37.0168
SK-LMS-1 GDSC1; GDSC2 -1.761 1.5037 -2.1643 29.7511
SK-UT-1 GDSC1; GDSC2 -1.6289 1.8257 -2.1304 28.95
EW-8 GDSC1; GDSC2 -1.6204 1.6577 -2.063 28.5722
Rh41 GDSC1; GDSC2 -1.5742 4.3574 -3.1168 32.9644
A-204 GDSC1; GDSC2 -0.9463 3.909 -2.2804 26.6393
SW872 GDSC1; GDSC2 -0.9252 1.6313 -1.3019 21.3502
G-401 GDSC1; GDSC2 -0.7048 3.0106 -1.6314 22.2584
RKN GDSC1; GDSC2 -0.5536 1.5255 -0.8633 17.2694
MES-SA GDSC1; GDSC2 0.2444 4.7046 -1.5143 18.0444
GCT GDSC1; GDSC2 1.0033 9.1599 -3.0772 23.3472
STS-0421 GDSC1 1.1879 9.4563 -3.0726 26.3877
RD GDSC1; GDSC2 1.3455 6.5994 -1.5173 14.6421
SW684 GDSC1; GDSC2 1.9279 3.9584 0.204 2.895
Rh18 GDSC1 4.9395 14.1034 -2.6318 14.2287
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OCUM-1 GDSC1; GDSC2 -2.1972 5.5731 -4.2952 39.2662
23132/87 GDSC1; GDSC2 -1.7548 2.6173 -2.5629 31.5824
TMK-1 GDSC1 -1.5995 5.9234 -3.8614 40.8892
NUGC-3 GDSC1; GDSC2 -0.8978 4.9541 -2.7181 28.4469
HSC-39 GDSC1; GDSC2 -0.4203 7.4355 -3.4665 29.5532
SNU-1 GDSC1; GDSC2 -0.3802 5.0567 -2.2685 24.329
MKN45 GDSC1; GDSC2 -0.3355 4.1456 -1.7886 21.6698
AGS GDSC1; GDSC2 0.1179 6.0112 -2.274 22.5493
HGC-27 GDSC1; GDSC2 0.7905 5.9129 -1.6331 16.9371
SNU-5 GDSC1; GDSC2 1.2589 3.5676 -0.0749 6.0885
SNU-16 GDSC1; GDSC2 1.27 4.8734 -0.7166 10.0764
RF-48 GDSC1; GDSC2 1.4043 3.1783 0.2267 3.8388
SK-GT-2 GDSC1; GDSC2 1.4289 6.7361 -1.5189 14.4185
TGBC11TKB GDSC1; GDSC2 1.4767 4.6734 -0.4562 7.9122
MKN28 GDSC1; GDSC2 1.4809 4.7038 -0.468 7.9751
SCH GDSC1 1.5343 4.8906 -0.5199 10.1147
GCIY GDSC1; GDSC2 1.5749 6.0862 -1.0814 11.4776
IM95 GDSC1; GDSC2 1.6626 3.5633 0.2196 3.3139
ECC10 GDSC1; GDSC2 1.7284 9.3945 -2.6068 19.2079
MKN1 GDSC1; GDSC2 1.8756 7.301 -1.4539 12.864
KATO III GDSC1; GDSC2 1.9893 5.3773 -0.4291 6.5318
NCI-N87 GDSC1; GDSC2 2.0197 14.4141 -4.8773 26.8029
RERF-GC-1B GDSC1; GDSC2 2.2156 6.3355 -0.7352 7.8664
Fu97 GDSC1; GDSC2 2.4664 10.2569 -2.4705 16.6722
MKN7 GDSC1; GDSC2 2.9192 8.9594 -1.5162 10.7764
Hs 746.T GDSC1; GDSC2 3.1908 10.4718 -2.0578 13.004
NUGC-4 GDSC1; GDSC2 3.5137 7.1365 -0.3132 3.2505
SNG-M GDSC1; GDSC2 -0.6171 1.5017 -0.9234 17.8846
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC1; GDSC2 -4.2807 -1.3898 -4.3274 52.8589
BHT-101 GDSC1; GDSC2 -3.9707 0.1811 -4.225 49.897
K5 GDSC1; GDSC2 -3.5633 0.2486 -3.7968 46.2471
CGTH-W-1 GDSC1; GDSC2 -3.2053 0.8942 -3.5609 43.234
TT2609-C02 GDSC1; GDSC2 -1.8061 0.9334 -2.0445 29.3726
CAL-62 GDSC1; GDSC2 -0.6737 2.7855 -1.5005 21.4011
KMH-2 GDSC1 -0.6533 2.7073 -1.4454 25.9517
ASH-3 GDSC1; GDSC2 -0.6277 5.5767 -2.7545 27.5271
ML-1 [Human leukemia] GDSC1 -0.3497 6.92 -3.1484 32.7563
HTC-C3 GDSC1; GDSC2 -0.1622 4.1034 -1.6017 19.9872
TT GDSC1; GDSC2 -0.1269 5.139 -2.0701 22.3887
B-CPAP GDSC1; GDSC2 1.0761 4.3263 -0.6002 9.8954
8305C GDSC1; GDSC2 1.5381 6.2876 -1.2099 12.3358
FTC-133 GDSC1; GDSC2 1.6105 7.3614 -1.6874 14.8633
8505C GDSC1; GDSC2 2.4661 9.9196 -2.3048 15.8769
WRO GDSC1; GDSC2 2.7408 7.0914 -0.7459 6.8454
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-38 GDSC1 -2.5364 5.0962 -4.4256 46.9923
KON GDSC1 -2.4953 3.4259 -3.6706 46.0298
SAS GDSC1; GDSC2 -2.442 2.2008 -3.1413 37.3921
BICR 10 GDSC1; GDSC2 -2.3325 4.1981 -3.8241 38.8135
BICR 22 GDSC1; GDSC2 -2.3305 1.5733 -2.806 35.5462
HSC-3 GDSC1; GDSC2 -1.979 2.6101 -2.7984 33.6803
PCI-06A GDSC1 -1.9083 0.243 -2.004 36.8991
PCI-04B GDSC1 -1.47 1.4626 -1.8348 33.0474
JHU-022 GDSC1; GDSC2 -1.3332 5.4471 -3.3765 32.8267
JHU-029 GDSC1 -1.2219 9.0528 -5.0006 41.1234
Ca9-22 GDSC1; GDSC2 -1.2062 2.4602 -1.9193 25.9374
JHU-011 GDSC1 -1.156 0.9589 -1.3418 28.1392
BICR 78 GDSC1; GDSC2 -0.8846 5.9487 -3.1787 30.2596
KOSC-2 GDSC1 -0.771 2.6231 -1.5309 27.1255
UPCI-SCC-090 GDSC1; GDSC2 -0.6622 9.7716 -4.8379 34.451
HO-1-u-1 GDSC1; GDSC2 -0.5429 7.7667 -3.7418 30.9444
CAL-33 GDSC1; GDSC2 -0.2671 3.9648 -1.6363 20.5715
BHY GDSC1 -0.2036 3.0226 -1.1314 21.5662
BB30-HNC GDSC1 -0.0817 3.8117 -1.3847 22.6875
NCI-H3118 GDSC1; GDSC2 0.0007 4.253 -1.5194 18.9281
HSC-2 GDSC1; GDSC2 0.1556 5.2776 -1.8776 20.3698
HO-1-N-1 GDSC1; GDSC2 0.2137 3.8979 -1.147 15.9962
FaDu GDSC1; GDSC2 0.4155 4.4029 -1.2102 15.6877
HSC-4 GDSC1; GDSC2 0.579 11.8027 -4.7561 30.3285
OSC-20 GDSC1; GDSC2 0.694 3.5025 -0.5146 10.511
Detroit 562 GDSC1; GDSC2 0.7826 4.8901 -1.129 14.0236
SKN-3 GDSC1; GDSC2 0.9021 5.7584 -1.4613 15.6168
BB49-HNC GDSC1; GDSC2 0.9277 6.4522 -1.7866 17.3659
PE/CA-PJ15 GDSC1 0.9444 8.6088 -2.8509 26.3158
CAL-27 GDSC1; GDSC2 0.9974 2.8107 0.0925 5.7533
PCI-30 GDSC1; GDSC2 1.0232 9.5279 -3.2446 23.9713
SCC-4 GDSC1; GDSC2 1.0627 7.2058 -2.0508 18.368
DOK GDSC1; GDSC2 1.1596 4.8763 -0.8068 10.9412
SCC-15 GDSC1; GDSC2 1.4317 9.8867 -3.0889 22.1537
SCC-25 GDSC1 1.6558 10.6247 -3.2774 25.6521
SCC-9 GDSC1; GDSC2 2.256 8.3553 -1.6907 13.2287
SAT [Human HNSCC] GDSC1; GDSC2 2.4781 9.1828 -1.9345 13.9862
LB771-HNC GDSC1; GDSC2 2.6065 11.427 -2.9428 18.4691
PCI-15A GDSC1 2.8037 4.4528 0.4466 0.812
OSC-19 GDSC1 3.347 4.9542 0.4784 0.3622
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
T24 GDSC1 -7.6675 9.8104 -11.7595 63.9923
BFTC-905 GDSC1; GDSC2 -2.3487 1.7515 -2.8842 35.9508
UM-UC-3 GDSC1; GDSC2 -0.7501 1.467 -1.0552 19.2054
647V GDSC1; GDSC2 0.2822 1.7608 -0.0703 9.2008
SW1710 GDSC1; GDSC2 0.6763 4.5087 -1.0309 13.7621
RT-112 GDSC1; GDSC2 0.6955 5.8288 -1.6726 17.456
KU-19-19 GDSC1; GDSC2 1.1006 3.2171 -0.0259 6.2082
J82 GDSC1; GDSC2 1.1435 5.2878 -1.0255 12.3242
639V GDSC1; GDSC2 1.1704 3.4722 -0.0971 6.4654
CAL-29 GDSC1; GDSC2 1.201 6.062 -1.3655 14.1796
5637 GDSC1; GDSC2 1.2342 3.9771 -0.2982 7.5598
SW780 GDSC1; GDSC2 1.5057 5.2735 -0.7313 9.5384
TCCSUP GDSC1; GDSC2 1.8713 4.6206 -0.1457 5.076
HT-1376 GDSC1; GDSC2 1.9659 5.0791 -0.3015 5.8134
HT-1197 GDSC1; GDSC2 2.641 5.8139 -0.2159 4.0294
RT-4 GDSC1; GDSC2 6.9813 22.8156 -5.4165 18.6641
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEY GDSC1; GDSC2 -2.9155 1.1491 -3.3148 40.7115
SiSo GDSC1; GDSC2 -2.0903 5.5589 -4.1812 38.5143
NEC8 GDSC1; GDSC2 -1.7705 3.8932 -3.1119 33.8586
JEG-3 GDSC1 -1.2081 5.3151 -3.1917 37.1002
PA-1 GDSC1; GDSC2 -1.176 1.6179 -1.5681 23.9272
C-33 A GDSC1; GDSC2 -1.0327 3.0017 -1.9644 25.4164
OVCA433 GDSC1 -0.8598 8.8289 -4.555 38.8146
PEO1 GDSC1; GDSC2 -0.8267 8.9744 -4.5959 34.4309
JAR GDSC1 -0.3715 2.9581 -1.2698 23.3406
OMC-1 [Human cervical carcinoma] GDSC1 -0.3501 6.1846 -2.7885 31.381
HT-3 GDSC1; GDSC2 0.0902 3.3515 -0.9993 15.5442
TC-YIK GDSC1; GDSC2 0.1201 2.6833 -0.6534 13.3384
OVMIU GDSC1; GDSC2 0.2424 11.1129 -4.7009 31.1837
CAL-39 GDSC1; GDSC2 0.2434 2.6969 -0.5393 12.1914
NT2-D1 GDSC1; GDSC2 0.2592 3.6107 -0.9645 14.7378
ACC-OV7 GDSC1 0.5412 5.7115 -1.7482 22.2253
SW756 GDSC1; GDSC2 0.5835 16.3943 -7.0469 35.1819
SKG-IIIa GDSC1; GDSC2 0.7627 7.5769 -2.4882 21.4623
BPH-1 GDSC1; GDSC2 0.7789 4.6879 -1.0312 13.4437
KGN GDSC1; GDSC2 0.8476 2.1875 0.2749 5.0543
C-4-I GDSC1; GDSC2 0.9178 10.9537 -4.0455 27.1998
Ca Ski GDSC1; GDSC2 0.933 7.7641 -2.4381 20.6968
DSH1 GDSC1; GDSC2 1.0784 3.6767 -0.2736 7.8361
SKN GDSC1; GDSC2 1.1031 7.9651 -2.397 19.9869
ME-180 GDSC1; GDSC2 1.1291 4.3835 -0.5854 9.6529
SW962 GDSC1 1.1574 11.4677 -4.1033 30.1823
HeLa GDSC1; GDSC2 1.3768 10.0943 -3.2371 22.9173
OV17R GDSC1 1.3949 11.6025 -3.9759 29.0104
JHOS-3 GDSC1 1.4112 10.0821 -3.2031 26.1574
PWR-1E GDSC1; GDSC2 1.4373 9.9279 -3.105 22.2047
DoTc2 4510 GDSC1; GDSC2 1.4632 4.2619 -0.2628 6.7423
SiHa GDSC1; GDSC2 1.4871 9.333 -2.7679 20.6078
HEC-1 GDSC1; GDSC2 1.5654 4.1104 -0.1128 5.5611
MS751 GDSC1; GDSC2 1.9065 3.9417 0.1985 2.9654
SW954 GDSC1 1.9356 4.0527 0.165 3.8668
OVCA420 GDSC1; GDSC2 2.0937 7.6722 -1.4743 12.434
LB831-BLC GDSC1; GDSC2 2.3024 9.2075 -2.0754 15.1344
UWB1.289 GDSC1 3.5755 12.1494 -2.6017 17.1803
NCC-IT GDSC2 4.6483 16.7259 -4.0694 18.4615
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cytarabine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [18]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Cytarabine and Roflumilast. Asthma [CA23] [20]
Ofloxacin DM0VQN3 Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [21]
Sparfloxacin DMB4HCT Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [21]
Gemifloxacin DMHT34O Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [21]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [21]
ABT-492 DMJFD2I Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [21]
Levofloxacin DMS60RB Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [21]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Cannabidiol. Epileptic encephalopathy [8A62] [20]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [22]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Cytarabine and Mipomersen. Hyper-lipoproteinaemia [5C80] [23]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Cytarabine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [24]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Cytarabine and BMS-201038. Hyper-lipoproteinaemia [5C80] [25]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Cytarabine and Denosumab. Low bone mass disorder [FB83] [26]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [27]
Fludarabine DMVRLT7 Moderate Additive myelosuppressive effects by the combination of Cytarabine and Fludarabine. Malignant haematopoietic neoplasm [2B33] [28]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Idelalisib. Mature B-cell leukaemia [2A82] [29]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Cytarabine and Thalidomide. Multiple myeloma [2A83] [30]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Cytarabine and Tecfidera. Multiple sclerosis [8A40] [31]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Cytarabine and Siponimod. Multiple sclerosis [8A40] [18]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Cytarabine and Fingolimod. Multiple sclerosis [8A40] [32]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Cytarabine and Ocrelizumab. Multiple sclerosis [8A40] [33]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Cytarabine and Ozanimod. Multiple sclerosis [8A40] [20]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Cytarabine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [34]
Gatifloxacin DMSL679 Minor Decreased absorption of Cytarabine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [21]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Cytarabine and Canakinumab. Rheumatoid arthritis [FA20] [35]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Cytarabine and Rilonacept. Rheumatoid arthritis [FA20] [35]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Cytarabine and Golimumab. Rheumatoid arthritis [FA20] [36]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Cytarabine and Leflunomide. Rheumatoid arthritis [FA20] [24]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Cytarabine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [37]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Cytarabine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [20]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Cytarabine and Azathioprine. Transplant rejection [NE84] [18]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Cytarabine and Ganciclovir. Virus infection [1A24-1D9Z] [18]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Cytarabine and Valganciclovir. Virus infection [1A24-1D9Z] [18]
⏷ Show the Full List of 35 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cytarabine 100mg/5ml solution 100mg/5ml Solution Intravenous; Subcutaneous
Cytarabine 2g/20ml solution 2g/20ml Solution Intravenous; Subcutaneous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4827).
2 Cytarabine FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
8 FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
9 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12 Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20.
13 Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
14 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
15 Protein kinase CbetaII activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2alpha down-regulation. J Biol Chem. 1997 Sep 19;272(38):23481-4. doi: 10.1074/jbc.272.38.23481.
16 Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
17 Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
18 Cerner Multum, Inc. "Australian Product Information.".
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
22 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
23 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
24 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
25 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
26 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
27 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
28 Gandhi V, Estey E, Keating MJ, Plunkett W "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy." J Clin Oncol 11 (1993): 116-24. [PMID: 8418222]
29 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
30 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
31 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
32 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
33 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
34 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
35 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
36 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
37 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]